Drug Trial Radar · NCT06628310
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
185
Actual
Start
Dec 13, 2024
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is given in combination with Fluorouracil, Leucovorin, and a programmed cell death receptor 1 (PD1) inhibitor Budigalimab. The combination (AFLB) will be given to adult participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA). Telisotuzumab Adizutecan (ABBV-400) and Budigalimab are investigational drugs being developed for the treatment of mGEA. Fluorouracil and Leucovorin are drugs approved for the treatment of mGEA. This study will be divided into two stages, with the first stage treating participants with increasing doses of ABBV-400 within the AFLB regimen until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into groups called treatment arms where one group will receive Budigalimab and FOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) . A further two treatment groups will receive AFLB, but with two optimized doses of ABBV-400 to allow for the best dose to be studied in the future. Approximately 180 adult participants with mGEA will be enrolled in the study in 51 sites worldwide. In the dose escalation stage, participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan (ABBV-400) within the AFLB regimen until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage, participants will receive FOLFOX or receive AFLB, but with one of two optimized doses of ABBV-400. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
Interventions
Telisotuzumab AdizutecanDrug
Intravenous (IV) Infusion
BudigalimabDrug
IV Infusion
FluorouracilDrug
IV Infusion; IV Injection
LeucovorinDrug
IV Infusion; IV Injection
OxaliplatinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by InvestigatorTime frame: Through Study Completion, Approximately 6 Years
- Percentage of Participants with Objective Response (OR) as Assessed by InvestigatorTime frame: Through Study Completion, Approximately 6 Years
Locations
49 sites in 11 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center /ID# 268690
Duarte, California
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630
Irvine, California
UCLA - Santa Monica /ID# 270024
Santa Monica, California
AdventHealth Orlando /ID# 268561
Orlando, Florida
City Of Hope - Atlanta /ID# 280646
Newnan, Georgia
Hattiesburg Clinic /ID# 268572
Hattiesburg, Mississippi
Duke University Medical Center /ID# 268186
Durham, North Carolina
Millennium Physicians /ID# 268540
Houston, Texas
CHU de Liege /ID# 270223
Liège, Belgium
Algemeen Ziekenhuis klina /ID# 268754
Brasschaat, Antwerpen, Belgium
Universitair Ziekenhuis Leuven /ID# 269957
Leuven, Vlaams-Brabant, Belgium
Princess Margaret Cancer Centre /ID# 268277
Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 268763
Montreal, Quebec, Canada
Jewish General Hospital /ID# 268413
Montreal, Quebec, Canada
Beijing Cancer Hospital /ID# 268455
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences(Langfang) /ID# 277479
Langfang, Hebei, China
Harbin Medical University Cancer Hospital /ID# 268452
Harbin, Heilongjiang, China
Union Hospital - Tongji Medical College /ID# 268796
Wuhan, Hubei, China
The first Affiliated Hospital, Zhejiang University School of Medicine. /ID# 268782
Hangzhou, Zhejiang, China
Haematologisch-Onkologische Praxis Eppendorf /ID# 268024
Hamburg, Germany
Universitaetsklinikum Freiburg /ID# 270407
Freiburg im Breisgau, Baden-Wurttemberg, Germany
TUM Klinikum rechts der Isar /ID# 267792
Munich, Bavaria, Germany
Krankenhaus Nordwest /ID# 268462
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Leipzig /ID# 270432
Leipzig, Saxony, Germany
Shaare Zedek Medical Center /ID# 267752
Jerusalem, Israel
Hadassah Medical Center-Hebrew University /ID# 267753
Jerusalem, Israel
Meir Medical Center /ID# 267998
Kefar Sava, Central District, Israel
Soroka Medical Center /ID# 268301
Beersheba, Southern District, Israel
Tel Aviv Sourasky Medical Center /ID# 267755
Tel Aviv, Tel Aviv, Israel
Aichi Cancer Center /ID# 268124
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East /ID# 268083
Kashiwa-shi, Chiba, Japan
Shizuoka Cancer Center /ID# 268123
Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital /ID# 268648
Chuo-Ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR /ID# 268656
Koto-ku, Tokyo, Japan
Pan American Center for Oncology Trials - Rio Piedras /ID# 268833
Rio Piedras, Puerto Rico
Hospital General Universitario Gregorio Maranon /ID# 270037
Madrid, Spain
Complexo Hospitalario Universitario de Ourense /ID# 270042
Ourense, Spain
Hospital Clinico Universitario de Valencia /ID# 270040
Valencia, Spain
Hospital Universitario de Navarra /ID# 270119
Pamplona, Navarre, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267672
Kaohsiung City, Taiwan
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.